CORDIS
Forschungsergebnisse der EU

CORDIS

Deutsch DE

Cutaneous and Mucosal HIV Vaccination

Ziel

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUT’HIVAC consortium gathers knowledge’s and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUT’HIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU® candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUT’HIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordinator

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

Adresse

Place Jussieu 4
75252 Paris

Frankreich

Aktivitätstyp

Higher or Secondary Education Establishments

EU-Beitrag

€ 1 963 463,30

Kontakt Verwaltung

Lucie Salvaudon (Dr.)

Beteiligte (17)

Alphabetisch sortieren

Nach EU-Beitrag sortieren

Alles aufklappen

NOVAMEN SAS

Frankreich

EU-Beitrag

€ 368 306

UNIVERSITAET REGENSBURG

Deutschland

EU-Beitrag

€ 1 270 801

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA

Spanien

EU-Beitrag

€ 974 680

FIT BIOTECH OY

Finnland

EU-Beitrag

€ 1 648 460

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Deutschland

EU-Beitrag

€ 621 400

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

Vereinigtes Königreich

EU-Beitrag

€ 119 326,50

Investigaciones Medicas en Salud

Peru

EU-Beitrag

€ 130 899,74

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Frankreich

EU-Beitrag

€ 759 760

MEDICAL RESEARCH COUNCIL

Vereinigtes Königreich

EU-Beitrag

€ 108 095,64

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Frankreich

EU-Beitrag

€ 96 811,04

Instituto Nacional de Saúde

Mosambik

EU-Beitrag

€ 241 334

ACIES Consulting Group SAS

Frankreich

GENEART AG

Deutschland

EU-Beitrag

€ 109 599

ASOCIACION CIVIL IMPACTA SALUD Y EDUCACION

Peru

EU-Beitrag

€ 282 338

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Vereinigtes Königreich

EU-Beitrag

€ 2 963 186,32

OBJECTIF RECHERCHE VACCIN SIDA

Frankreich

EU-Beitrag

€ 30 966,60

UNIVERSITY COLLEGE LONDON

Vereinigtes Königreich

EU-Beitrag

€ 239 822,86

Projektinformationen

ID Finanzhilfevereinbarung: 241904

Status

Abgeschlossenes Projekt

  • Startdatum

    1 Januar 2010

  • Enddatum

    31 Dezember 2015

Finanziert unter:

FP7-HEALTH

  • Gesamtbudget:

    € 15 439 854,26

  • EU-Beitrag

    € 11 929 250

Koordiniert durch:

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

Frankreich